Maximizing Quality of Life From the Get-Go in Neuro-Oncology Care

Commentary
Video

Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.

The goal of preserving quality of life (QOL) and extending the lives of patients with brain tumors remains “front and center” in neuro-oncology care, according to Sylvia Kurz, MD, PhD.

Kurz, an associate professor of neurology (neuro-oncology) as part of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center, spoke with CancerNetwork® about key considerations for optimizing QOL and mitigating treatment-related toxicities that may occur among patients who undergo therapy for high-grade gliomas and other brain cancers. She stated that toxicities such as bone marrow suppression or chemotherapy-associated liver toxicity are typically manageable with strategies including dose modifications and symptomatic care.

In the neuro-oncology field, Kurz stated that clinicians typically think about potential symptoms and focus on the quality of care from the get-go. Additionally, she emphasized that severe long-term complications were usually rare among patients who received treatment for brain tumors.

Transcript:

The guidepost in neuro-oncology care in general is to maximize quality of life at any given time point. At this point, for many of these illnesses, including the high-grade gliomas, we’re not going for a cure, but the goal is to extend life and preserve quality of life as much as we can. That should be front and center for any treatment decisions.

Treatment-related toxicities in today’s neuro-oncology medicine probably [include] bone marrow suppression, kidney or liver toxicity from various forms of chemotherapies, and then the immunotherapy-related [adverse] effects. They are generally well managed with dose modifications, holding cycles of treatments, or symptomatic measures or care. Another big point of treatment-related toxicities is radiation-associated toxicities, where we use a drug called bevacizumab [Avastin] to help patients feel better and improve neurological symptoms.

The key consideration here is to always think about symptoms in patients and focus on quality of care from the get-go. I would also say that this is typically accomplished, and patients do as well as they can. Long-term severe complications are relatively rare in our field.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.